Navigation Links
AAP expands ages for diagnosis and treatment of ADHD in children
Date:10/15/2011

BOSTON Updated guidelines from the American Academy of Pediatrics (AAP) offer new information on diagnosing and treating Attention-Deficit/Hyperactivity Disorder (ADHD) in younger children and in adolescents.

Emerging evidence makes it possible to diagnose and manage ADHD in children from ages 4 to 18 (the previous AAP guidelines, from 2000 and 2001, covered children ages 6 to 12). The new guidelines describe the special considerations involved in diagnosing and treating preschool children and adolescents. They also include interventions to help children with hyperactive/impulsive behaviors that do not meet the full diagnostic criteria for ADHD.

"Treating children at a young age is important, because when we can identify them earlier and provide appropriate treatment, we can increase their chances of succeeding in school," said Mark Wolraich, MD, FAAP, lead author of the report. "Because of greater awareness about ADHD and better ways of diagnosing and treating this disorder, more children are being helped."

ADHD is the most common neurobehavioral disorder in children, occurring in about 8 percent of children and youth.

The report, "ADHD: Clinical Practice Guidelines for the Diagnosis, Evaluation and Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder," will be released Sunday, October 16, at the AAP National Conference & Exhibition in Boston, and will be published in the November 2011 issue of Pediatrics (published online Oct. 16). Dr. Wolraich will discuss the new recommendations during an embargoed news briefing for reporters at 9 a.m. ET Saturday, Oct. 15, at the Boston Convention & Exhibition Center.

According to the AAP guidelines, in preschool children (ages 4 and 5) with ADHD, doctors should first try behavioral interventions, such as group or individual parent training in behavior management techniques. Methylphenidate may be considered for preschool children with moderate to severe symptoms who do not see significant improvement after behavior therapy, starting with a lower dose. For elementary school children and adolescents, the AAP recommends both FDA-approved medications and behavior therapy.

"Because ADHD is a chronic condition, it requires a team approach, including the patients, their parents, the pediatrician, therapists, and teachers," Dr. Wolraich said.

In addition to the formal recommendations for assessment, diagnosis and treatment of ADHD, the guidelines provide a single algorithm to guide the clinical process. The AAP is also releasing a newly revised and updated ADHD Toolkit to assist health care providers diagnose and treat ADHD in their patients. To help parents understand the new guidance on ADHD, the AAP has published a detailed and updated consumer resource book entitled "ADHD: What Every Parent Needs to Know." Parent information will also be available at www.healthychildren.org/adhd starting Oct. 16.


'/>"/>

Contact: Susan Martin
ssmartin@aap.org
847-434-7131
American Academy of Pediatrics
Source:Eurekalert

Related medicine news :

1. Toys"R"Us, Inc. Expands its Support of Autism Speaks Throughout North America
2. Carpet and Rug Institute Expands Seal of Approval Program
3. Language Service Leader Expands to Meet Booming, Global Industry Demand.
4. Bluegiga Expands to Health and Medical Market With the New Bluegiga eHealth Access Point
5. SRI International Expands Neurosciences Research with New Neurodegenerative Diseases Research Program
6. Estes Audiology Expands to Boerne in Association with Jim Atkins, M.D.
7. California Dental Association Foundation Expands Care to States Underserved Communities
8. Kaplan Continuing Education Expands Health Care Certificate Programs
9. Sociologist expands US conversation on human rights
10. First Coast Service Options (FCSO) Expands Use of Burgess Products
11. Surgeon General with Microsoft HealthVault Expands Consumer Benefits for the My Family Health Portrait Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: